Courtesy: Shahnoor Habib Munmum/Wikimedia Commons
The issue of foreign direct investment in pharmaceuticals has come under attack from many lobbies. The answers lie in the public sector or public distribution mechanisms. Addressing public health concerns without vitiating the investment climate must be one of the key priorities of the next government
Courtesy: Legaleagle86/Wikimedia Commons
Policy Perspectives from Gateway House give an overview of a global issue that has implications for India’s policy-making and business community. This edition focuses on the global IPR framework and the need for new business models that can cater to public health concerns
This daily column includes Gateway House’s Badi Soch – big thought – of the day’s foreign policy events. Today’s focus is on the $500 million fine levied on Ranbaxy by the U.S. Food and Drug Administration.
Courtesy: Leoboudv/WikimediaCommons
Often, many vital inventions are left incomplete or do not reach the market as information is locked up by numerous patent holders. How does this hamper innovation, and why is it necessary to overcome the attitude of ‘anti-commons’ and foster cross-fertilization of knowledge?